Emerging therapeutic options for eosinophilic esophagitis.

Timothy Dougherty, Sindu Stephen, Marie L Borum, David B Doman

Open access · greenAbstract read

In one paragraph

Article in Gastroenterology & hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

0.6field-weighted citation impact, top 31% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants: A Randomized Phase 1 Study.Journal of clinical pharmacology · 2025
Trial
Eosinophilic esophagitis in children: doubts and future perspectives.Journal of translational medicine · 2019
Review
Monoclonal Antibodies for Treatment of Eosinophilic Esophagitis.Clinical reviews in allergy & immunology · 2018
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Timothy DoughertyDr Dougherty is a fellow and Dr Borum is a professor of medicine and chair in the Division of Gastroenterology and Liver Diseases at The George Washington University in Washington, DC. Both doctors are also affiliated with The George Washington University Medical Faculty Associates. Dr Stephen is an office-based gastroenterologist in Silver Spring, Maryland. Dr Doman is a clinical professor of medicine at The George Washington University.

Sindu StephenDr Dougherty is a fellow and Dr Borum is a professor of medicine and chair in the Division of Gastroenterology and Liver Diseases at The George Washington University in Washington, DC. Both doctors are also affiliated with The George Washington University Medical Faculty Associates. Dr Stephen is an office-based gastroenterologist in Silver Spring, Maryland. Dr Doman is a clinical professor of medicine at The George Washington University.

Marie L BorumDr Dougherty is a fellow and Dr Borum is a professor of medicine and chair in the Division of Gastroenterology and Liver Diseases at The George Washington University in Washington, DC. Both doctors are also affiliated with The George Washington University Medical Faculty Associates. Dr Stephen is an office-based gastroenterologist in Silver Spring, Maryland. Dr Doman is a clinical professor of medicine at The George Washington University.

David B DomanDr Dougherty is a fellow and Dr Borum is a professor of medicine and chair in the Division of Gastroenterology and Liver Diseases at The George Washington University in Washington, DC. Both doctors are also affiliated with The George Washington University Medical Faculty Associates. Dr Stephen is an office-based gastroenterologist in Silver Spring, Maryland. Dr Doman is a clinical professor of medicine at The George Washington University.

George Washington University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophilic esophagitis (EoE) is a chronic inflammatory condition of the esophagus that often occurs in atopic persons. Management strategies include pharmacotherapy, dietary modification, and endoscopic therapy, although patients will often have a relapsing and remitting course. Currently, the primary pharmacotherapy for EoE consists of corticosteroids. Immuno-modulators, leukotriene antagonists, biologies, and monoclonal antibodies are currently under study for treatment of EoE. The role of immunoglobulin E-mediated allergic reactions has been well documented and may provide insight into the etiology and effective therapy of EoE.

Indexed as

Eosinophilic esophagitisproton pump inhibitor—responsive esophageal eosinophiliareflux esophagitis

Identifiers

PMID24803874

PMCPMC4011375

OpenAlexW1582466941

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.